Results of clinical studies of the efficacy and safety of the use of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia

This article is in “Library” – “Neurology” – “CCR: Chronic Cerebrovascular Disorder” section.

Author:
M.V. ZHURAVLEVA1,2, P.R. KAMCHATNOV3, N.S. VASYUKOVA4, V.V. ARKHIPOV1, E.V. KUZNETSOVA5, T.R. KAMENEVA6, S.YU. SEREBROVA1,2

1Research Center for Examination of Medical Devices, Moscow, Russia;
2Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
3Pirogov Russian National Research Medical University, Moscow, Russia;
4Skriabin and Kovalenko Institute of Experimental Veterinary Medicine, Moscow, Russia;
5Research Institute for Healthcare and Medical Management, Moscow, Russia;
6Konchalovsky City Clinical Hospital, Moscow, Russia

Read more.


Results of clinical studies of the efficacy and safety of the use of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia

Author:
M.V. ZHURAVLEVA1,2, P.R. KAMCHATNOV3, N.S. VASYUKOVA4, V.V. ARKHIPOV1, E.V. KUZNETSOVA5, T.R. KAMENEVA6, S.YU. SEREBROVA1,2

1Research Center for Examination of Medical Devices, Moscow, Russia;
2Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
3Pirogov Russian National Research Medical University, Moscow, Russia;
4Skriabin and Kovalenko Institute of Experimental Veterinary Medicine, Moscow, Russia;
5Research Institute for Healthcare and Medical Management, Moscow, Russia;
6Konchalovsky City Clinical Hospital, Moscow, Russia

Summary:
Chronic cerebral ischemia (CCI) is a common syndrome that, in the absence of adequate therapy, is characterized by a progressive course, an increase in cognitive, emotional, motor and other disorders, eventually leading to persistent disability of the patient. In the treatment of patients with CCI, the use of drugs with a multimodal neuroprotective effect is indicated. The results of the analysis of a series of clinical trials of the drugs Mexidol and Mexidol FORTE in patients with CCI are presented. The effects in relation to cognitive, emotional, asthenic, vegetative and other manifestations of CCI are considered. It is concluded that it is advisable to consistently use the drugs Mexidol and Mexidol FORTE in such patients. Keywords: chronic cerebral ischemia, cognitive impairment, Mexidol, emotional disorders, treatment.


Efficacy of Mexidol in patients with chronic brain ischemia and cognitive impairment of different age groups (results of sub-analysis of the international multicenter, randomized, double-blind, placebo-controlled study of sequential therapy in patients with chronic brain ischemia MEMO)

This article is in “Library” – “Neurology” - "CCR: Chronic Cerebrovascular Disorder" section.

Author:
V.V. ZAKHAROV1, O.N. TKACHEVA2,3, E.A. MKHITARYAN2,3, A.I. FEDIN2

1Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
2Pirogov Russian National Research Medical University , Moscow, Russia;
3Russian Clinical and Research Center of Gerontology, Pirogov Russian National Research Medical University , Moscow, Russia

Read more.


Efficacy of Mexidol in patients with chronic brain ischemia and cognitive impairment of different age groups (results of sub-analysis of the international multicenter, randomized, double-blind, placebo-controlled study of sequential therapy in patients with chronic brain ischemia MEMO)

Author:
V.V. ZAKHAROV1, O.N. TKACHEVA2,3, E.A. MKHITARYAN2,3, A.I. FEDIN2

1Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
2Pirogov Russian National Research Medical University , Moscow, Russia;
3Russian Clinical and Research Center of Gerontology, Pirogov Russian National Research Medical University , Moscow, Russia

Summary:
Objective. To assess the efficacy of sequential therapy with Mexidol and Mexidol FORTE 250 in comparison with placebo in patients of different age groups with chronic brain ischemia. Material and methods. The study is sub-analysis of data of the international multicenter, randomized, double-blind, placebo-controlled study of sequential therapy in patients with chronic brain ischemia (MEMO), which included 318 patients (25% men) in the age of 40—90 (median 60) years. All subjects were subdivided into 3 age subgroups: 40—60 years (n=163), 61—75 years (n=141) and 76—90 years (n=13). The primary efficacy endpoint was the dynamic of increase of total score by MoCA scale, i.e. the absolute value of difference by MoCA scale at the point of day 75 comparing to values before treatment. As secondary efficacy endpoints results of dynamic by following questionnaires and scales were used: digit symbol substitution test, the Health Survey SF-36, asthenia subjective assessment scale (MFI-20), Vane questionnaire, Beck anxiety scale, Tinetti scale. Results. After 75 days of treatment positive dynamic was revealed in cognitive, emotional and motor impairment in patients of 40—60 and 61—75 age subgroups both in groups of Mexidol and placebo, but in group of Mexidol the changes were more prominent which is proved by significantly higher values of median of absolute difference of total score of studied parameters. Conclusion. The results of trial showed that in patients of different age-subgroups with chronic brain ischemia the improvement in cognitive, motor impairment and quality of life, as well as decrease in vegetative impairment, asthenia and anxiety are observed after 75 days of treatment both in Mexidol and placebo group, but in Mexidol group these changes are more prominent. The data obtained confirm the expediency of the use of sequential therapy with Mexidol and Mexidol FORTE 250 in patients of different age subgroups with chronic brain ischemia. Keywords: cognitive impairment, chronic brain ischemia, Mexidol , Mexidol FORTE 250, ethylmethylhydroxypyridine succinate, MEMO trial.


Cognitive impairments in cardiological patients: diagnosis and prevention

This article is in "Library" - "Cardiology" section.

Author:

E.K. SHAVAROVA1,2, A.A. SHAVAROV1, R.E. AKHMETOV3, Z.D. KOBALAVA1,2

1Peoples Friendship University of Russia (RUDN University), Moscow, Russia;

2City Clinical Hospital named after V.V. Vinogradov, Moscow, Russia

3LLC «Scientific and production company «PHARMASOFT», Moscow, Russia

Read more.


Use and outcomes of antioxidant therapy in ophthalmic practice

This article is in "Library" - "Ophthalmology" section.

Author:

A.B. MOVSISYAN1,2, ZH.G. OGANEZOVA2,3, E.A. EGOROV2

1Hospital for War Veterans No. 2, Moscow, Russia;

2Pirogov Russian National Research Medical University, Moscow, Russia;

3N.P. Bochkov Research Centre for Medical Genetics, Moscow, Russia

Read more.


Use and outcomes of antioxidant therapy in ophthalmic practice

Author:
A.B. MOVSISYAN1,2, ZH.G. OGANEZOVA2,3, E.A. EGOROV2

1Hospital for War Veterans No. 2, Moscow, Russia;

2Pirogov Russian National Research Medical University, Moscow, Russia;

3N.P. Bochkov Research Centre for Medical Genetics, Moscow, Russia

Summary:
Advances in medical diagnostic technologies, particularly in ophthalmology, help researchers understand histological characteristics of the human eye and study vision at the cellular level. In addition to its role in the ocular function associated with the control of movements, senses and protective responses, the nervous system plays a key role in regulation of the visual process. Neurodegenerative disorders hold a special place among systemic diseases. Presently, the development of such pathologies are associated with neuroinflammation, which has been proven to also contribute to the glaucomatous process. For this reason, achieving target intraocular pressure does not always guarantee stabilization of the degenerative process. In this context, neuroprotective agents are recommended for glaucoma management to all patients taking into consideration pathogenetic characteristics of the disease. Based on its antioxidative and neuroprotective effects, ethylmethylhydroxypyridine succinate (Mexidol) is commonly used in ophthalmic practice, specifically in the treatment of patients with glaucomatous optic neuropathy and retinal diseases. The results of studies demonstrate that Mexidol is effective in slowing down neurodegeneration and stabilizing visual functions in patients with primary open-angle glaucoma due to its antihypoxic, antioxidant and membrane-stabilizing properties, as well as its positive impact on the neuromediator balance and ocular blood flow.
Keywords: ophthalmology, eye, neuroinflammation, glaucoma, glaucomatous optic neuropathy, neuroprotective therapy, ethylmethylhydroxypyridine succinate, Mexidol, Mexidol FORTE 250.


Cognitive impairments in cardiological patients: diagnosis and prevention

Author:
E.K. SHAVAROVA1,2, A.A. SHAVAROV1, R.E. AKHMETOV3, Z.D. KOBALAVA1,2

1Peoples Friendship University of Russia (RUDN University), Moscow, Russia;

2City Clinical Hospital named after V.V. Vinogradov, Moscow, Russia

3LLC «Scientific and production company «PHARMASOFT», Moscow, Russia

Summary: 
The development of preventive measures to reduce the risk of developing cognitive decline is named by WHO among the main priorities of medicine. Cardiovascular diseases and cognitive disorders, on the one hand, have similar risk factors, such as obesity, smoking, dyslipidemia, lack of physical activity, low education level, and, on the other hand, the presence of atrial fibrillation (AF), arterial hypertension (AH), cardiac insufficiency (HF), chronic kidney disease, diabetes mellitus contributes to the progression of cognitive impairment. In the era of patient-oriented medicine, when choosing the optimal treatment regimen for AH, AF, and HF, it is necessary to take into account the potential of certain therapy regimens in the prevention of cognitive impairment. This article is devoted to a review of existing therapeutic strategies to prevent the development of cognitive deficits in patients with a cardiological profile.
Keywords: cognitive impairment, dementia, arterial hypertension, atrial fibrillation, heart failure, mexidol.


Safety of Mexidol® (ethylmethylhydroxypyridine succinate) in adult patients of different age groups

This article is in "Library" - "Chronic cerebrovascular disorder" section.

Author:

E.A. USHKALOVA1, S.K. ZYRYANOV1,2, O.I. BUTRANOVA1

1RUDN University, Moscow; 2City Clinical Hospital No. 24, Department of Healthcare of Moscow, Moscow

Read more.


Safety of Mexidol® (ethylmethylhydroxypyridine succinate) in adult patients of different age groups

Author:
E.A. USHKALOVA1, S.K. ZYRYANOV1,2, O.I. BUTRANOVA1

1RUDN University, Moscow; 2City Clinical Hospital No. 24, Department of Healthcare of Moscow, Moscow

Summary:
To reduce the risk of developing adverse events (AEs) and increase the adherence of elderly patients to treatment, it is recommended to limit maximally the total number of prescribed drugs (DR), using one drug for the treatment of two or more pathologies if possible. The drugs that meet the criteria for use in elderly patients and / or patients with comorbidity include the original Russian drug Mexidol® (ethylmethylhydroxypyridine succinate), which has a multimodal mechanism of action and has multiple pharmacological effects. In order to study the safety of Mexidol in comparison with placebo in different age groups of patients with chronic cerebral ischemia, a post hoc analysis of the international multicenter, randomized, double-blind, placebo-controlled MEMO study with an adaptive design was carried out, which assessed the efficacy and safety of sequential therapy with Mexidol®, a solution for intravenous and intramuscular injection, 50 mg/ml (NPK PHARMASOFT, Russia) and Mexidol® FORTE 250 film-coated tablets, 250 mg (NPK PHARMASOFT, Russia) in patients with chronic cerebral ischemia. The study involved 318 patients aged from 40 to 90 years. Comparable safety and tolerability of Mexidol was demonstrated in middle-aged and elderly people with chronic cerebral ischemia, including patients over 75 years of age. Keywords: adult patients of different age groups; elderly; MEMO research; Mexidol®; Mexidol® FORTE 250; ethylmethylhydroxypyridine succinate; safety.